)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
AstraZeneca Pharma India
AstraZeneca Pharma India (506820) investor relations material
AstraZeneca Pharma India Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary5 Nov, 2026
Executive summary
Q2 FY27 revenue from operations was Rs 7,291.0 million; profit after tax was Rs 623.3 million, including exceptional expenses of Rs 149.6 million.
H1 FY27 revenue was Rs 14,118.9 million and profit after tax was Rs 1,002.6 million; operating cash flow was Rs 2,323.8 million.
Financial highlights
Q2 revenue from operations Rs 7,291.0 million vs Rs 5,590.9 million YoY; total income Rs 7,442.2 million vs Rs 5,652.6 million.
Q2 profit before exceptional items and tax Rs 1,034.5 million vs Rs 781.1 million YoY; profit after tax Rs 623.3 million vs Rs 542.2 million.
H1 revenue from operations Rs 14,118.9 million vs Rs 10,854.0 million; profit before exceptional items and tax Rs 1,544.4 million vs Rs 1,531.7 million.
H1 profit after tax Rs 1,002.6 million vs Rs 1,100.5 million; basic and diluted EPS Rs 40.10 vs Rs 44.02.
Q2 basic and diluted EPS Rs 24.93 vs Rs 21.69 YoY; exceptional expenses were Rs 149.6 million, versus Rs 52.9 million YoY.
Segment performance
Healthcare was identified as the sole reportable segment.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from AstraZeneca Pharma India
- Revenue up 29% and net profit up 63%, with Oncology leading growth and a ₹24/share dividend proposed.506820
Q4 23/24 - 30% revenue growth and strategic milestones highlight a strong Q1 FY2026-27 performance.506820Q1 26/27
- 33% revenue growth and robust profit, driven by innovation and new approvals in key therapy areas.506820Q4 25/26
- Q3 FY25-26 revenue grew 39% year-over-year, driven by strong therapy area performance and innovation.506820Q3 25/26
- 32% revenue growth and robust product launches drive strong FY 2024-25 results.506820Q4 24/25
- Exceptional expense for site closure resulted in a quarterly net loss despite higher revenue.506820Q1 24/25
- Net profit declined due to a major provision for site closure, despite higher revenue.506820Q2 24/25
- Revenue surged 44% year-over-year in Q3 2024, led by Oncology and Biopharmaceuticals growth.506820Q3 24/25
- Q1 FY25-26 revenue up 36% YoY, profit after tax at ₹558.3M, four new therapy approvals.506820Q1 25/26
Next AstraZeneca Pharma India earnings date
Q3 26/275 Feb, 2027
AstraZeneca Pharma India
Next AstraZeneca Pharma India earnings date
Q3 26/275 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)